Literature DB >> 20647188

Don't mess with the DSMB.

Jeffrey M Drazen, Alastair J J Wood.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20647188     DOI： 10.1056/NEJMe1007445

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.

Authors:  Neil A Goldenberg; Alex C Spyropoulos; Jonathan L Halperin; Craig M Kessler; Sam Schulman; Alexander G G Turpie; Allan M Skene; Neal R Cutler; William R Hiatt
Journal:  Blood       Date:  2010-11-10       Impact factor: 22.113

2.  Addressing risks to advance mental health research.

Authors:  Ana S Iltis; Sahana Misra; Laura B Dunn; Gregory K Brown; Amy Campbell; Sarah A Earll; Anne Glowinski; Whitney B Hadley; Ronald Pies; James M Dubois
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

3.  Data monitoring committees: Promoting best practices to address emerging challenges.

Authors:  Thomas R Fleming; David L DeMets; Matthew T Roe; Janet Wittes; Karim A Calis; Amit N Vora; Alan Meisel; Raymond P Bain; Marvin A Konstam; Michael J Pencina; David J Gordon; Kenneth W Mahaffey; Charles H Hennekens; James D Neaton; Gail D Pearson; Tomas Lg Andersson; Marc A Pfeffer; Susan S Ellenberg
Journal:  Clin Trials       Date:  2017-02-01       Impact factor: 2.486

Review 4.  Reporting of data monitoring boards in publications of randomized clinical trials is often deficient: ACTTION systematic review.

Authors:  Jennifer S Gewandter; Rachel A Kitt; Matthew R Hunsinger; Joseph Poku; Jacqueline Lozano; Jenna Chaudari; Scott Evans; Robert A Gross; Michael P McDermott; Michael C Rowbotham; Dennis C Turk; Robert H Dworkin
Journal:  J Clin Epidemiol       Date:  2017-01-23       Impact factor: 6.437

5.  Designing Oversight for Nanomedicine Research in Human Subjects: Systematic Analysis of Exceptional Oversight for Emerging Technologies.

Authors:  Susan M Wolf; Cortney Jones
Journal:  J Nanopart Res       Date:  2011-04       Impact factor: 2.253

Review 6.  Protecting clinical trial participants and protecting data integrity: are we meeting the challenges?

Authors:  Susan S Ellenberg
Journal:  PLoS Med       Date:  2012-06-12       Impact factor: 11.069

Review 7.  Impact of data transparency: Scientific publications.

Authors:  Mohit Joshi; Payal Bhardwaj
Journal:  Perspect Clin Res       Date:  2018 Jan-Mar

Review 8.  Corporate practices and health: a framework and mechanisms.

Authors:  Joana Madureira Lima; Sandro Galea
Journal:  Global Health       Date:  2018-02-15       Impact factor: 4.185

9.  Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).

Authors:  Charles L Bennett; Shamia Hoque; Nancy Olivieri; Matthew A Taylor; David Aboulafia; Courtney Lubaczewski; Andrew C Bennett; Jay Vemula; Benjamin Schooley; Bartlett J Witherspoon; Ashley C Godwin; Paul S Ray; Paul R Yarnold; Henry C Ausdenmoore; Marc Fishman; Georgne Herring; Anne Ventrone; Juan Aldaco; William J Hrushesky; John Restaino; Henrik S Thomsen; Paul R Yarnold; Robert Marx; Cesar Migliorati; Salvatore Ruggiero; Chadi Nabhan; Kenneth R Carson; June M McKoy; Y Tony Yang; Martin W Schoen; Kevin Knopf; Linda Martin; Oliver Sartor; Steven Rosen; William K Smith
Journal:  EClinicalMedicine       Date:  2020-12-23

10.  The Essential Role of Data and Safety Monitoring Boards (DSMBs) in Ensuring the Ethics of Global Vaccine Trials to Address Coronavirus Disease 2019 (COVID-19O).

Authors:  Lisa Eckstein; Annette Rid; Dorcas Kamuya; Seema K Shah
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.